Related Experiment Video
Updated: Jun 30, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Alex J Eustace1, John Crown, Martin Clynes
1National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland. Alex.eustace@dcu.ie
Background:
Metastatic melanoma is a highly chemotherapy resistant tumour. The use of newer targeted therapies alone and in combination with chemotherapy may offer new hope of improving response to treatment. Dasatinib, a multi-target kinase inhibitor, is currently approved for the treatment of chronic myeloid leukaemia and has shown promising results in preclinical studies in a number of solid tumours.
Methods:
We examined the effects of dasatinib on proliferation, chemo-sensitivity, cell cycle arrest, apoptosis, migration and invasion in human melanoma cell lines. Expression and activation of Src kinase, FAK and EphA2 were also examined in the melanoma cells.
Results:
Dasatinib inhibited growth of three of the five melanoma cell lines. Comparison with sorafenib showed that in these three cell lines dasatinib inhibited growth at lower concentrations than sorafenib. Dasatinib in combination with the chemotherapy drug temozolomide showed greater efficacy than either drug alone. Dasatinib induced cell cycle arrest and apoptosis and significantly inhibited cell migration and invasion of melanoma cells. Dasatinib inhibition of proliferation was associated with reduced phosphorylation of Src kinase, while decreased phosphorylation of FAK was implicated in dasatinib-mediated inhibition of migration and invasion in melanoma cells.
Conclusion:
Dasatinib has both anti-proliferative and anti-invasive effects in melanoma cells and combined with chemotherapy may have clinical benefit in the treatment of malignant melanoma.
Insights
Dasatinib, a targeted therapy, shows anti-proliferative and anti-invasive effects in melanoma cells. Combining dasatinib with chemotherapy may improve treatment outcomes for metastatic melanoma.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Metastatic melanoma is a difficult-to-treat cancer with high chemotherapy resistance.
- Targeted therapies offer potential new treatment strategies for melanoma.
- Dasatinib, a kinase inhibitor, has shown preclinical promise in solid tumors.
Purpose of the Study:
- To investigate the effects of dasatinib on human melanoma cell lines.
- To evaluate dasatinib's impact on proliferation, chemo-sensitivity, cell cycle, apoptosis, migration, and invasion.
- To examine the expression and activation of key kinases (Src, FAK, EphA2) in response to dasatinib.
Main Methods:
- Treatment of human melanoma cell lines with dasatinib.
- Assessment of cell proliferation, chemo-sensitivity, cell cycle arrest, apoptosis, migration, and invasion.
- Analysis of Src kinase, FAK, and EphA2 expression and phosphorylation levels.
Main Results:
- Dasatinib inhibited melanoma cell growth in three of five cell lines, often at lower concentrations than sorafenib.
- Combination therapy with dasatinib and temozolomide demonstrated enhanced efficacy compared to monotherapy.
- Dasatinib induced cell cycle arrest, apoptosis, and significantly reduced cell migration and invasion.
- Inhibition of proliferation correlated with reduced Src kinase phosphorylation; inhibition of migration/invasion was linked to decreased FAK phosphorylation.
Conclusions:
- Dasatinib exhibits both anti-proliferative and anti-invasive properties in melanoma cells.
- Combination of dasatinib with chemotherapy may offer clinical benefits for malignant melanoma patients.
- Targeted inhibition of specific kinases by dasatinib provides a potential therapeutic avenue for melanoma.
